Displaying drugs 8026 - 8043 of 8043 in total
Amibegron
Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Investigational
Cositecan
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Investigational
Tesofensine
Investigational
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
Iclaprim
Investigational
Nelipepimut-S
Investigational
Thymoquinone
Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
Investigational
Perifosine
Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.
Investigational
Oleic monoethanolamide
Investigational
V24343
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
RAF-265
Investigational
TAS-106
TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours .
Investigational
CYP-001
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.
The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
Mito-4509
Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
Investigational
ING-1
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
PR-104
Investigational
ALTU-135
ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. ALTU-135 has been granted orphan drug...
Investigational
Displaying drugs 8026 - 8043 of 8043 in total